stoxline Quote Chart Rank Option Currency Glossary
  
Chemomab Therapeutics Ltd. (CMMB)
0.68  -0.02 (-2.86%)    04-19 16:00
Open: 0.7399
High: 0.7399
Volume: 15,575
  
Pre. Close: 0.7
Low: 0.657
Market Cap: 10(M)
Technical analysis
2024-04-19 5:08:33 PM
Short term     
Mid term     
Targets 6-month :  0.85 1-year :  0.96
Resists First :  0.73 Second :  0.82
Pivot price 0.74
Supports First :  0.57 Second :  0.48
MAs MA(5) :  0.67 MA(20) :  0.74
MA(100) :  0.62 MA(250) :  0.96
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  34 D(3) :  21.6
RSI RSI(14): 43.6
52-week High :  1.88 Low :  0.41
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CMMB ] has closed above bottom band by 22.7%. Bollinger Bands are 55.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.74 - 0.75 0.75 - 0.75
Low: 0.65 - 0.65 0.65 - 0.66
Close: 0.67 - 0.68 0.68 - 0.69
Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Headline News

Tue, 05 Mar 2024
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference - Yahoo Finance

Wed, 14 Feb 2024
CMMB Stock Quote Price and Forecast - CNN

Wed, 14 Feb 2024
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update - Yahoo Finance

Mon, 05 Feb 2024
Chemomab Therapeutics to Participate in Upcoming February 2024 Investor Conferences - BioSpace

Tue, 30 Jan 2024
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing ... - PR Newswire

Wed, 06 Dec 2023
Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 14 (M)
Shares Float 188 (M)
Held by Insiders 14.9 (%)
Held by Institutions 24.9 (%)
Shares Short 222 (K)
Shares Short P.Month 244 (K)
Stock Financials
EPS -2.06
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.2
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -48.8 %
Return on Equity (ttm) -91.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.79
Qtrly Earnings Growth 0 %
Operating Cash Flow -24 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -0.34
PEG Ratio 0
Price to Book value 0.56
Price to Sales 0
Price to Cash Flow -0.41
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android